We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ISRG's Software Strategy Becoming as Important as Its Robots?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical rolled out the first phase of more than 100 planned da Vinci 5 software updates.
My Intuitive renewals began in Q2, with no customers in the initial cohort opting out.
Service revenues rose 21%, while revenue per da Vinci system increased 8%, partly due to da Vinci 5.
Intuitive Surgical’s (ISRG - Free Report) software is increasingly becoming a core component of the da Vinci 5 value proposition, potentially extending the platform’s competitive moat beyond hardware. The company rolled out the first phase of more than 100 planned software updates during the second quarter, targeting telepresence, simulation-based training and Care Team workflow. Management also submitted multiple innovations for FDA 510(k) clearance, suggesting that the software roadmap is designed as an ongoing stream of capability enhancements rather than a one-time product launch.
The commercial significance is already evident in My Intuitive+, Intuitive Surgical’s integrated da Vinci 5 offering that combines telepresence, simulation, and AI-driven case insights. The company executed its first wave of My Intuitive+ renewals during the second quarter. Although the initial renewal cohort was small, no customer opted out, providing an early indication that customers see continuing value in the digital layer surrounding the robotic platform.
The roadmap also extends into practical workflow improvements. Three submitted features include tools designed to reduce communication between surgeons and care teams, improve multi-arm adjustments and introduce a digital ruler that allows surgeons to measure anatomy during procedures. Management said additional updates will focus on improving system efficiency and effectiveness, with further differentiated capabilities expected over the coming years.
This strategy could make da Vinci 5 increasingly difficult to evaluate purely as capital equipment. Continuous software enhancements can improve usability, efficiency and clinical capabilities after installation, encouraging customers to remain within the Intuitive ecosystem and supporting the company's broader recurring-revenue model. The second-quarter service revenues increased 21%, while service revenue per da Vinci system rose 8%, partly reflecting the higher mix of da Vinci 5 systems.
Peer Update
For competitors, the implication is significant — matching robotic hardware may not be enough. Intuitive Surgical is building a layered ecosystem spanning robotics, software, AI, training and workflow optimization. ISRG management believes these capabilities, supported by sustained R&D investment, can meaningfully differentiate its solutions and reduce total cost of care.
Stryker (SYK - Free Report) is also embedding digital capabilities into its Mako ecosystem to make robotic surgery more effective while creating a broader technology moat. Mako has evolved into a multispecialty platform spanning hip, knee, spine and shoulder, with more than 2.5 million procedures across 47 countries.
The company’s strategy increasingly links robotics with enabling technologies and procedural workflows, while the full commercial launch of Mako RPS adds a handheld option for surgeons and ASCs. Stryker is using clinical evidence and continuous product innovation to deepen adoption rather than relying solely on hardware placements. With record Mako installations and rising utilization, this integrated approach strengthens surgeon familiarity, builds procedural data advantages, and increases ecosystem stickiness, potentially making Mako harder for competitors to displace.
Zimmer Biomet (ZBH - Free Report) is building its robotic moat by combining ROSA with a broader technology-and-data ecosystem. The company delivered record capital sales in the second quarter, driven by ROSA with OptimiZe, TMINI and the next-generation ROSA Shoulder, while its Technology & Data, Bone Cement and Surgical category grew 21.5%.
Beyond robotics, Zimmer is integrating digital tools such as OrthoGrid, an AI-based navigation solution for direct anterior hip procedures that delivered its strongest quarter and is expected to accelerate. ROSA Shoulder further differentiates the platform through an improved interface and the ability to perform both anatomic and reverse procedures with humeral and glenoid resections. By combining robotics, AI navigation, data and differentiated workflows, Zimmer is building a broader technology ecosystem that can improve surgical precision while increasing customer engagement and competitive defensibility.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 31.1% so far this year compared with an 8.1% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 10.88X, above the industry average. But it is significantly lower than its five-year median of 15.78X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Is ISRG's Software Strategy Becoming as Important as Its Robots?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) software is increasingly becoming a core component of the da Vinci 5 value proposition, potentially extending the platform’s competitive moat beyond hardware. The company rolled out the first phase of more than 100 planned software updates during the second quarter, targeting telepresence, simulation-based training and Care Team workflow. Management also submitted multiple innovations for FDA 510(k) clearance, suggesting that the software roadmap is designed as an ongoing stream of capability enhancements rather than a one-time product launch.
The commercial significance is already evident in My Intuitive+, Intuitive Surgical’s integrated da Vinci 5 offering that combines telepresence, simulation, and AI-driven case insights. The company executed its first wave of My Intuitive+ renewals during the second quarter. Although the initial renewal cohort was small, no customer opted out, providing an early indication that customers see continuing value in the digital layer surrounding the robotic platform.
The roadmap also extends into practical workflow improvements. Three submitted features include tools designed to reduce communication between surgeons and care teams, improve multi-arm adjustments and introduce a digital ruler that allows surgeons to measure anatomy during procedures. Management said additional updates will focus on improving system efficiency and effectiveness, with further differentiated capabilities expected over the coming years.
This strategy could make da Vinci 5 increasingly difficult to evaluate purely as capital equipment. Continuous software enhancements can improve usability, efficiency and clinical capabilities after installation, encouraging customers to remain within the Intuitive ecosystem and supporting the company's broader recurring-revenue model. The second-quarter service revenues increased 21%, while service revenue per da Vinci system rose 8%, partly reflecting the higher mix of da Vinci 5 systems.
Peer Update
For competitors, the implication is significant — matching robotic hardware may not be enough. Intuitive Surgical is building a layered ecosystem spanning robotics, software, AI, training and workflow optimization. ISRG management believes these capabilities, supported by sustained R&D investment, can meaningfully differentiate its solutions and reduce total cost of care.
Stryker (SYK - Free Report) is also embedding digital capabilities into its Mako ecosystem to make robotic surgery more effective while creating a broader technology moat. Mako has evolved into a multispecialty platform spanning hip, knee, spine and shoulder, with more than 2.5 million procedures across 47 countries.
The company’s strategy increasingly links robotics with enabling technologies and procedural workflows, while the full commercial launch of Mako RPS adds a handheld option for surgeons and ASCs. Stryker is using clinical evidence and continuous product innovation to deepen adoption rather than relying solely on hardware placements. With record Mako installations and rising utilization, this integrated approach strengthens surgeon familiarity, builds procedural data advantages, and increases ecosystem stickiness, potentially making Mako harder for competitors to displace.
Zimmer Biomet (ZBH - Free Report) is building its robotic moat by combining ROSA with a broader technology-and-data ecosystem. The company delivered record capital sales in the second quarter, driven by ROSA with OptimiZe, TMINI and the next-generation ROSA Shoulder, while its Technology & Data, Bone Cement and Surgical category grew 21.5%.
Beyond robotics, Zimmer is integrating digital tools such as OrthoGrid, an AI-based navigation solution for direct anterior hip procedures that delivered its strongest quarter and is expected to accelerate. ROSA Shoulder further differentiates the platform through an improved interface and the ability to perform both anatomic and reverse procedures with humeral and glenoid resections. By combining robotics, AI navigation, data and differentiated workflows, Zimmer is building a broader technology ecosystem that can improve surgical precision while increasing customer engagement and competitive defensibility.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 31.1% so far this year compared with an 8.1% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 10.88X, above the industry average. But it is significantly lower than its five-year median of 15.78X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.